Video-Tumorboard PLUS
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital Muenster
About this trial
In weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. By further developing and optimizing the CCCs' video tumor boards, initially using skin cancer as an example, we want to ensure that more patients can benefit from the expertise of several specialist disciplines and innovations - regardless of where they live.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
The study includes adult, external patients who, according to the certification requirements of the German Cancer Society, should be presented to the CCCs in a tumor board .
Minimum age 18 years
Malignant melanoma from stage IIB
Malignant melanoma and stage shift/recurrence o Extracutaneous melanoma o Cutaneous lymphoma from stage Ib o Problem cases with malignant, epithelial tumors (BCC, SCC) with interdisciplinary issues, e.g. complicated localization, extension/ infiltration (e.g. Ulcus rodens, Ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including Merkel cell carcinoma, DFSP, MFH, leiomyosarcoma, S., Kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: An external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the CCC) . This also applies to patients who are only seen once at the vTB.
Disqualifiers
Linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy.
No consent to participate in the study (patient consent) or withdrawal of consent during the course of the study In addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.
Trial population
As part of the vTB+ study, an evaluation of the video tumor board is to be carried out for as broad a section of the population as possible. Women of childbearing potential with and without contraception make up a relevant proportion of the population. Participation in the study is not associated with physical interventions, so that the contraceptive status of fertile participants is irrelevant. Even in the case of pregnancy, participation in the study would be harmless. The exclusion of women of childbearing potential with and without contraception from the vTB+ study would therefore represent a gender-based disadvantage.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
300 Participants
are grouped into 2 trial groupsGroup A: 1
Group B: 2
Trial outcomes
Primary outcomes
1
Presentation of external patients in the video-tumorboard
Increase in the proportion of external patients in the video-tumorboard
Time frame
Day 365Secondary outcomes
1
Increase in the proportion of external patients invited to a clinical study
Increase in the proportion of external patients in clinical studies
Time frame
Day 3652
Adherence to tumorboard recommendations for external patients
Proportion of implemented tumorboard recommendations for external patients
Time frame
Up to two weeks after inclusion3
Offer of supportive therapies by the comprehensive cancer center
Proportion of (external) patients who are offered at least one supportive therapy (e.g. psychooncology) within the video-tumorboard
Time frame
Up to two days after inclusion4
Duration of the transmission of the tumorboard recommendations
Duration of the transmission of the tumorboard recommendations
Time frame
Up to two weeks after inclusionSponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital Muenster
Lead sponsor
Deutsche Krebshilfe e.V., Bonn (Germany)
Collaborator
University Hospital, Bonn
Collaborator
University Hospital Dresden
Collaborator
Source ClinicalTrials.gov